Bank of Nova Scotia
ALXN

Bank of Nova Scotia’s Alexion Pharmaceuticals ALXN Stock Holding History

Bank of Nova Scotia’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,104,245
Closed -$203M – 1231
2021
Q2 		$203M Buy
1,104,245
+31,666
+3% +$5.44M 0.37% 61
2021
Q1 		$164M Buy
1,072,579
+1,031,241
+2,495% +$160M 0.32% 74
2020
Q4 		$6.46M Buy
41,338
+8,118
+24% +$1.04M 0.01% 448
2020
Q3 		$3.8M Buy
+33,220
New +$3.58M 0.01% 510
2020
Q2 		– Sell
-192,524
Closed -$17.3M – 1075
2020
Q1 		$17.3M Sell
192,524
-41,952
-18% -$4.12M 0.06% 234
2019
Q4 		$25.4M Buy
234,476
+189,497
+421% +$20.3M 0.06% 243
2019
Q3 		$4.41M Buy
44,979
+1,995
+5% +$225K 0.01% 506
2019
Q2 		$5.63M Buy
42,984
+394
+0.9% +$50.8K 0.02% 395
2019
Q1 		$5.76M Sell
42,590
-5,017
-11% -$624K 0.02% 408
2018
Q4 		$4.63M Buy
47,607
+2,321
+5% +$274K 0.02% 426
2018
Q3 		$6.29M Buy
45,286
+20,851
+85% +$2.62M 0.03% 386
2018
Q2 		$3.03M Sell
24,435
-3,782
-13% -$442K 0.02% 424
2018
Q1 		$3.14M Sell
28,217
-209,793
-88% -$25.1M 0.02% 469
2017
Q4 		$28.5M Buy
238,010
+199,242
+514% +$24.3M 0.13% 163
2017
Q3 		$5.44M Sell
38,768
-11,986
-24% -$1.63M 0.03% 356
2017
Q2 		$6.17M Sell
50,754
-676
-1% -$78.7K 0.03% 389
2017
Q1 		$6.24M Buy
51,430
+46,404
+923% +$5.98M 0.03% 365
2016
Q4 		$615K Sell
5,026
-23,530
-82% -$2.88M ﹤0.01% 566
2016
Q3 		$3.5M Buy
28,556
+6,060
+27% +$780K 0.02% 269
2016
Q2 		$2.63M Buy
22,496
+18,280
+434% +$2.59M 0.02% 266
2016
Q1 		$587K Buy
4,216
+20
+0.5% +$2.94K ﹤0.01% 451
2015
Q4 		$800K Sell
4,196
-40
-0.9% -$6.99K ﹤0.01% 421
2015
Q3 		$662K Buy
4,236
+630
+17% +$115K ﹤0.01% 374
2015
Q2 		$652K Buy
3,606
+94
+3% +$16.2K ﹤0.01% 326
2015
Q1 		$609K Buy
3,512
+142
+4% +$25.7K ﹤0.01% 331
2014
Q4 		$624K Buy
3,370
+160
+5% +$29.6K ﹤0.01% 329
2014
Q3 		$532K Buy
3,210
+102
+3% +$16.8K ﹤0.01% 351
2014
Q2 		$486K Buy
3,108
+167
+6% +$26.4K ﹤0.01% 363
2014
Q1 		$447K Buy
2,941
+261
+10% +$41.5K ﹤0.01% 400
2013
Q4 		$357K Buy
2,680
+230
+9% +$27.6K ﹤0.01% 427
2013
Q3 		$285K Sell
2,450
-249
-9% -$27.3K ﹤0.01% 428
2013
Q2 		$249K Buy
+2,699
New +$260K ﹤0.01% 426

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Bank of Nova Scotia's ALXN Position: Q3 2021 in Review

Bank of Nova Scotia sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,104,245 shares — an estimated $203M sold.

Bank of Nova Scotia first reported a position in ALXN in Q2 2013 and held it in 32 quarters. The position peaked at $203M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Bank of Nova Scotia reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Bank of Nova Scotia sold 1,104,245 Alexion Pharmaceuticals shares in Q3 2021, an estimated $203M.
  • Bank of Nova Scotia first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 32 quarters.
  • Bank of Nova Scotia's Alexion Pharmaceuticals position peaked at $203M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Bank of Nova Scotia's 13F filing for Q3 2021, filed 12 Nov 2021.